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Decorin is a prototype member of the small leucine-rich pro-
teoglycan family widely distributed in the extracellular matrices
of many connective tissues, where it has been shown to play
multiple important roles in the matrix assembly process, as
well as in some cellular activities. A major interest for decorin
function concerns its role in tumorigenesis, as growth-inhibitor
of different neoplastic cells, and potential antimetastatic agent.
The aim of our research was to investigate wide-ranged effects
of transgenic decorin on breast cancer cells. To this purpose we
utilized the well-characterized 8701-BC cell line, isolated from
a ductal infiltrating carcinoma of the breast, and two derived
decorin-transfected clones, respectively, synthesizing full decorin
proteoglycan or its protein core. The responses to the ectopic
decorin production were examined by studying morphological
changes, cell proliferation rates, and proteome modulation. The
results revealed new important antioncogenic potentialities, likely
exerted by decorin through a variety of distinct biochemical
pathways. Major effects included the downregulation of several
Received 26 June 2007; revised 3 September 2007; accepted 20
September 2007.
Address correspondence to Prof. Ida Pucci-Minafra, Dipartimento
di Oncologia Sperimentale e Applicazioni Cliniche, Via San Lorenzo
Colli 31290146 Palermo, Italy. E-mail: idapucci@unipa.it
potential breast cancer biomarkers, the reduction of membrane
ruffling, and the increase of cell-cell adhesiveness. These results
disclose original aspects related to the reversion of malignant traits
of a prototype of breast cancer cells induced by decorin. They also
raise additional interest for the postulated clinical application of
decorin.
Keywords Decorin, Breast cancer, Proteomics
INTRODUCTION
Recent advances in cancer research have reinforced the
concept that while initial stages of cancer are due to genetic
alterations, its progression toward higher levels of malignancy
is mainly sustained by epigenetic events, induced by signals
emanating from the host stroma. Indeed, the latter, rather
than being a passive scaffold, is a dynamic microenvironment
rich with potentially informative activities. The instructive
role of extracellular territories during embryogenesis and its
reoccurrence in cancer has been postulated or demonstrated by
several authors [1–4]. Collagen is the major component of the
extracellular matrix: its role on shaping stromal architecture
and cell-matrix communications in cancer has been described
30
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PROTEOMIC CHANGE IN DECORIN-TRANSFECTED BREAST CANCER 31
by several researchers [5–8]. In addition, the proteoglycan
superfamily has been shown to perform or support a variety
of extracellular functions [9].
Decorin, a prototype member of the small leucine-rich
proteoglycan family (SLRP), is widely distributed in many
connective tissues [10, 11], where it plays a structural role
because of its ability to bind collagens [12–16] and other
extracellular proteins [17–19]. Moreover, decorin is able to
interact with cells of different origin through a proposed
mechanism involving the epidermal growth factor receptor (s)
and a functional p21 [20, 21]. Through the latter pathway
decorin has been shown to exert a growth-suppressive effect,
to a different extent, in various tumor cell lines [22–24].
In spite of the large number of studies on the effects of decorin
as a putative antioncogenic factor, its wide-ranging consequence
on protein expression profile has not been investigated yet.
Due to these considerations, we aimed at investigating the in
vitro effects of decorin produced by a transgene on the proteomic
profile of breast cancer cells. For this study we utilized the
breast cancer cell line 8701-BC, well characterized also for the
proteomic profile [25–28], and two derived decorin-transfected
clones, respectively, synthesizing full decorin proteoglycan
(DEC-C2 clone) or its protein core (DEC-C3 clone). The
responses to the ectopic decorin production were examined
by monitoring cell proliferation rates, morphological changes,
and proteomic modulation. Our results illustrate for the first
time that ectopic decorin not only exerts a growth-retarding
effect on breast cancer cells, but also induces notable proteomic
modulation and cellular responses. The most significant are
the reversion of cell surface perturbation, decreased expression
levels of glycolytic enzymes, as well as of other candidate
biomarkers for breast cancer progression.
MATERIALS AND METHODS
Cell Culture
The breast cancer cell line 8701-BC, derived from a ductal
infiltrating carcinoma, was described previously [25]. Cells were
grown in RPMI 1640 medium (Invitrogen), with 10% (v/v)
fetal calf serum (FCS, Invitrogen), and 1% antibiotics (100 U
penicillin and 100 µg streptomycin/ml) and cultured at 37◦C in
a 5% CO2 atmosphere.
Decorin Expression Vector and Transfection
A decorin cDNA fragment corresponding to nt 172 to 1161
(decorin sequence MN001920) was isolated by RT-PCR from
human fibroblasts RNA with oligonucleotides containing 5′
overhang sequences with BamHI and XbaI restriction sites
(forward-TTGGGATCCGATGAGGCTTCTGGGATAGG, rev-
erse-TTGTCTAGATTACTTATAGTTTCC GAGTTG), and
cloned into the BamHI/XbaI sites of the pcDNA4/HisMax
expression vector (Invitrogen). To allow an efficient secretion
of the recombinant proteins, a specific peptide signal from the
V-J2-C region of the mouse Ig kappa-chain was then inserted
FIG. 1. Western blotting, using an anti-His tag antibody conjugated with
horseradish peroxidase on secreted proteins of four independent decorin-
transfected clones. Proteins from culture media were precipitated by 15%TCA
(final) and electrophoresed on 8% SDS PAGE. The clones designated DEC-C2,
expressing and secreting the full decorin proteoglycan (PG), and the clone
designated DEC-C3, which express and secrete the protein core, were selected
for this study.
between the start codon of the protein and the His-tag by cloning
a 78 bp double stranded oligonucleotide into the NcoI site of the
vector. In frame insertion and correct orientation of the cloned
fragments were confirmed by nucleotide sequencing.
Exponentially growing 8701-BC cells were transfected using
Lipofectamine Plus (Invitrogen) according to the manufacturer’s
instructions and maintained under selection for 14 days in
RPMI-1640 medium supplied with 10% FCS and 0.4 mg/ml
Zeocin. A reporter plasmid lacking decorin cDNA (mock-
transfection) was used as negative control.
Several clones were isolated and studied for decorin expres-
sion. Two independent clones were selected for present studies,
the clone designated DEC-C2, that expresses and secretes the
full decorin proteoglycan, and the clone designated DEC-C3,
that expresses and secretes the protein core (Figure 1).
Cell Proliferation Assays
Growth response of 8701-BC cells to ectopically expressed or
exogenously supplied decorin was determined by a colorimetric
MTS cell proliferation assay (Promega), according to the
manufacturer’s instructions. Cell proliferation was determined
at 24-hr intervals throughout a 7-day period. Decorin used
for the assays was extracted and purified from bovine tendon
as described previously [29], and each kinetic evaluation was
performed by supplementing the culture medium with three
different concentrations of the purified protein: 5, 7.5 and
10 µg/ml.
Scanning Electron Microscopy
At the established times the samples were processed for
SEM observation. The plates were carefully rinsed with PBS
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32 I. PUCCI-MINAFRA ET AL.
to prevent detachment of cells from the glass. Cells were
fixed with Karnowski solution (1.5% glutaraldehyde, 1%
paraformaldehyde, 1% cacodylate buffer, pH 7.4) for 10 min.
Plates with adhering cells were then rinsed three times with
0.1% cacodylate buffer, postfixed for 20 min with 1% OsO4
in cacodylate buffer, dehydrated with ethanol, and finally
dried with hexamethyldisilazane (Sigma) for 15 min. Then the
specimens were coated with 20 nm-thick palladium-gold film
and examined using a Philips SEM 515 at 15 kV.
Two Dimensional Gel Electrophoresis
Cells grown to confluence were deprived of serum and then
lysed in RIPA buffer as previously described [27]. Protein
concentration in the cellular extracts was determined by the
Bradford method [30]. Proteins were solubilized in ISOT buffer
(4% CHAPS, 40 mM Tris, 65 mM DTE in 8 M urea) and
aliquots of 45 µg (analytical gels) or 1.5 mg (preparative gels)
used for the electrophoretic separation. First dimension was
performed with IPG strips (18 cm, nonlinear pH range 3.5 to
10, Pharmacia); the 1D run was carried out by linearly increasing
voltage from 200 to 3500 V during the first 3 hr, after which
focusing was continued at 8000 V for 8 hr.
After the electrophoresis the IPG strips were equilibrated
with a solution containing 6 M urea, 30% glycerol, 2% SDS,
0.05 M Tris-HCl, pH 6.8, and 2% DTE for 12 min to resolubilize
proteins and reduce disulfide bonds. The -SH groups were then
blocked by substituting the DTE with 2.5% iodoacetamide
in the equilibrating buffer. The focused proteins were then
separated on 9–16% linear gradient polyacrylamide gels (SDS-
PAGE) with a constant current of 40 mA/gel at 10◦C. Gels
were stained with ammoniacal silver nitrate, digitized using
a computing densitometer, and processed with ImageMaster
2D platinum system (Amersham Biosciences). Absence of
discernible residual serum proteins was monitored by 2D-IPG
of FCS.
Protein Identification
The protein identity was assessed by N-terminal sequencing
and by gel matching with reference maps previously ob-
tained in our laboratory and available in the Expasy database
(http://www.expasy.ch/world-2dpage/) where identification was
performed by N-terminal microsequencing (Procise, 419 Ap-
plied Biosystems) and by MALDI-TOF (Voyager DE-PRO,
Applied-Biosystems) as described [28, 31]. Matching validation
relied on N-terminal sequencing of five randomly selected
protein spots, among the ones previously identified.
Protein Spot Quantification
Relative intensity of protein spots in the matched 2D
gels from parental and transfected cells was determined by
the densitometry algorithms of the Image Master software,
normalizing the data to the sum of all spot volumes on gels
(Vol%) [32, 33].
FIG. 2. (A) shows the growth rate of 8701-BC cell line and the two
selected decorin-transfected clones, DEC-C2 and DEC-C3, by using the MTS
colorimetric assay. (B) shows the growth curves of the 8701-BC control cells
and of cells exposed to exogenous decorin from days 4 to 7, at concentrations
of 5, 7.5, and 10 µg/ml respectively, by using the MTS colorimetric assay. Each
time point represents the mean of 4 replicates from two independent experiments
(± SD).
RESULTS
Ectopic and Exogenous Decorin and Cell Growth
To investigate the effect of decorin, either the entire
proteoglycan or its protein core, on the growth rate of our cellular
system, we performed parallel proliferation assays on the two
selected decorin-transfected clones, DEC-C2 and DEC-C3, and
on the parental 8701-BC cell line, by using the MTS colorimetric
assay as described in the previous section. Cell proliferation was
determined at 24, 48 and 96 hr, 5, 6 days and 7 days (Figure 2A).
The retarding effect of ectopic decorin on cell growth of both
DEC-C2 and DEC-C3 begins at 4 days from seeding. At 7 days
the growth rate of the two clones is significantly reduced: the
DEC-C2 shows a reduction of ∼50% with respect to the control
cells, whereas the DEC-C3 displays a reduction of 33% versus
the parental cell cultures. No differences were observed between
parental 8701-BC and mock-transfected cells, thus excluding
the occurrence of possible nonspecific effects caused by the
vector transfection (data not shown).
To verify if the decreased growth rate could be mediated by
cell surface receptorial apparatus, we repeated the proliferation
assays by incubating the parental 8701-BC cells with increasing
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PROTEOMIC CHANGE IN DECORIN-TRANSFECTED BREAST CANCER 33
quantities of exogenous decorin. Figure 2B shows the growth
curves of the parental cells and the curves of cells exposed
to exogenous decorin from days 4 to 7, at concentrations of
5, 7.5, and 10 µg/ml, respectively. The replicate experiments
clearly show that 8701-BC cells were responsive to extracellular
decorin in a dose-dependent way. At day 7 (i.e., after 3 days of
treatment) the number of cells exposed to 5 µg/ml of decorin
showed a 25% decrease versus the untreated controls, cells
treated with 7.5 µg/ml a decrease of 41%, and cells treated
with 10 µg/ml a decrease of 56%. For each concentration we
performed four replicates. These results are in good agreement
with results reported by other researchers on different cell lines
[22, 24].
Morphological Assays
Neoplastic cells, both in vivo and in vitro, display loss of
adhesion and anarchic growth, often correlated with extensive
membrane protrusions and vesiculation. To verify if ectopic
decorin could reverse or restrain these surface perturbations,
we performed morphological analyses of both transfected and
parental cell cultures by scanning electron microscope. The
images in Figure 3A clearly show the tremendous surface
ruffling and membrane shedding of 8701-BC cells, opposite
to a more regular outline of the transfected cells, both DEC-
C2 (Figure 3B) and DEC-C3 (Figure 3C). These results
indicate that decorin definitely restrains these aggressive-type
surface activities, reverting the cell morphology toward a more
differentiated phenotype.
Effect on 8701-BC Proteomic Expression Profiles
Figure 4A shows a representative proteomic map of the
parental 8701-BC cells, where the protein identities are marked
with labels corresponding to the abbreviated name of the
Swiss-Prot database. The number of protein spots in the map
is 130 corresponding to 78 genes. When present, the different
isoelectric forms of a protein are indicated with alphabetical
letters, starting with “a” at the more acidic pI.
Figures 4B and 4C show the miniature of representative
2D gels from DEC-C2 and DEC-C3 cultures, respectively.
The identified proteins were grouped into 6 functional cate-
gories, according to our previously described criteria [28]. In
detail, present categories are the followings: 1) cytoskeleton
and associated proteins, 2) metabolic enzymes, 3) molecu-
lar chaperones/heat shock proteins, 4) membrane-associated
and calcium binding proteins, 5) detoxification, degradation,
and related proteins, and 6) biosynthesis and proliferation
regulators.
A detailed description of comparative proteomic profiles of
DEC-C2 and DEC-C3 clones versus the parental 8701-BC cells
is given for each protein category in the histograms in Figure 5.
Each value is the average of three different gels. For graphical
limitations the SD values (5–10%) were not included in figures.
According to general criteria for gene expression amplitude,
the degree of the modulation was considered high (∗∗) for fold
values ≥ 2 and medium (∗) for values between 2.0 and 1.5.
Cytoskeleton and Associated Proteins
In this group we identified 28 protein spots corresponding
to 12 different proteins (Figure 5A), 5 of which are structural
proteins, actin (ACT, 6 isoforms), cytokeratin 9 (K1C9), tubulin
alpha-1 (TBA1, 3 isoforms), tubulin beta-5 (TBB5, 3 isoforms),
and vimentin (VIME, 5 isoforms). The others correspond to
actin-binding proteins: myosin light polypeptide 6 (MYL6),
cofilin (COF1, 2 isoforms), profilin 1 (PROF1, 2 isoforms),
ezrin (EZRI), tropomyosin beta (TPM2), tropomyosin alpha 4
(TPM4, 2 isoforms), and thymosin beta 4 (TYB4). We found that
structural proteins show modest modulation in the transfected
clones, whereas a higher degree of modulation was observed in
the subgroup of actin–binding proteins, which play pivotal roles
in the cytoskeleton reorganization. Among these, the decrease
of acidic forms of cofilin and profilin, and an increase of
tropomyosin and thymosin beta 4, were detected.
Metabolic Enzymes
Within this group of proteins we identified so far 27 spots,
corresponding to 16 different enzymes and isoforms (Figure
5B). Four of them correspond to the following mitochondrial
enzymes: aconitase (ACON), ATP synthase beta chain (ATPB),
cytochrome c oxidase polypeptide Va (COX5A), and malate
dehydrogenase (MDHM, 2 isoforms). Conversely, the majority
of protein spots belong to the anaerobic glycolytic pathway,
namely: fructose-biphosphate aldolase A (ALDOA, 2 isoforms),
enolase alpha (ENOA, 3 isoforms), glyceraldehyde-3-phosphate
dehydrogenase (G3P2, 5 isoforms), phosphoglycerate kinase
1 (PGK1, 2 isoforms), phosphoglycerate mutase 1(PGAM1),
pyruvate kinase (KPYM, 2 isoforms), triosephosphate iso-
merase (TPIS, 2 isoforms), and the final step-enzyme of the
anaerobic glycolysis the l-lactate dehydrogenase (LDH A and
B chains). A collective lowered expression (∼1.5/ 2 fold) of
glycolytic enzymes and significant increase of COX5A were
detected in both clones versus the parental cells. The other
proteins identified in this group are acyl-CoA dehydrogenase
(ACADS), retinal dehydrogenase 1 (AL1A1), and enoyl-CoA
hydratase (ECHM). ACADS was not detected in DEC-C2 and
DEC-C3 clones, while the others did not show significant
variations.
Molecular Chaperones/Heat Shock Proteins
In this group we have at present catalogued 25 protein spots
corresponding to 15 distinct proteins (Figure 5C). Some of them
belong to the classical heat shock protein families, namely: 94
kDa glucose-regulated protein (GRP94, 2 isoforms); several
components of the Hsp 70 family, i.e., 78 kDa glucose-regulated
protein (GRP78, 3 isoforms), 75 kDa glucose regulated protein
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34 I. PUCCI-MINAFRA ET AL.
FIG. 3. Scanning electron micrographs of (A) 8701-BC parental cell line, (B) DEC-C2 transfected clone, and (C) DEC-C3 transfected clone.
(magnification:1000X).
(GRP75), heat shock 70 kDa protein 1 (HSP71), heat shock
70 kDa protein 4 (HSP74), heat shock cognate 71 kDa protein
(HSP7C, 2 isoforms); 3 isoforms of the chaperonin HSP60 and 2
isoforms of HSP27, a member of the small heat shock proteins.
Other proteins included in this category display additional
activities related to different part of the molecules. Among
these proteins are the calreticulin (CRTC), 2 isoforms of the
protein disulfide isomerase A3 (PDIA3), the protein disulfide
isomerase A1 (PDIA1), 3 isoforms of the peptidyl-prolyl
cis-trans isomerase A (PPIA), the transitional endoplasmic
reticulum ATPase (TERA), and two chaperonines (TCTP and
TCPZ) involved in microtubule-stabilization and in the folding
of actin and tubulin. Significant variations within this category
were the increase of GRP94, HSP74, PDIA1, TCTP, the acidic
form of GRP78, and PPIA.
Membrane-Associated and Calcium-Binding Proteins
This group of proteins contains 19 spots corresponding to
10 distinct proteins (Figure 5D), belonging to the families of
annexins (2 isoforms of ANXA1, 2 isoforms of ANXA2, 2
isoforms of ANXA4 plus 3 short forms), galectins (LEG1 and
2 isoforms of LEG3), S100 calcium-binding (S10A4, S10AB,
2 isoforms of S10A6), calmodulin (CALM), and 2 isofoms of
voltage-dependent anion-selective channel protein 1(VDAC1).
A considerable modulation was detected for annexin 4, showing
an increase of its levels either in DEC-C2 and DEC-C3, and for
annexin 2, whose levels decrease in transfected cells. Among
the Ca-binding proteins we observed a significant increase of
calmodulin levels in DEC-C2 and DEC-C3. Calmodulin-Ca++
ions interaction stimulates a wide number of enzymatic proteins
and overall kinases and phosphatases involved in intracellular
signalling, cytoskeletal organization, and cell cycle control.
Conversely, a net decrease of S100A4 in DEC-C2 cells and
its absence in DEC-C3 were observed.
Detoxification, Degradation and Related Proteins
In this category we identified 20 protein spots corresponding
to 14 distinct proteins (Figure 5E). Nine belong to the
detox pathways: aldo-keto reductase family 1 (AK1C3 and 2
isoforms of AK1BA), aldose reductase (ALDR, 2 isoforms),
glutathione S-transferase P (GSTP1), peroxiredoxin 1 and
6 (PRDX1, 3 isoforms, and PRDX6), superoxide dismutase
[Cu-Zn] and [Mn] (SODC and SODM, 2 isoforms), thioredoxin
(THIO, 2 isoforms) and a thioredoxin-related protein, SH3
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PROTEOMIC CHANGE IN DECORIN-TRANSFECTED BREAST CANCER 35
FIG. 4. Representative proteomic maps of 8701-BC parental cell line (A). Protein spots of known identity are labelled with the abbreviated name of the
Swiss-Prot database. When present, different isoforms of the same protein are jointly labelled. Other abbreviation: sf = short form. (B) and (C) show the miniature
maps of DEC-C2 and DEC-C3 transfected clones respectively.
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36 I. PUCCI-MINAFRA ET AL.
FIG. 5. Histograms of differentially expressed proteins in 8701-BC cells and in the two selected clones. Relative intensity of protein spots was calculated
normalizing the data to the sum of all spot volumes on gels (vol%). Each value is the mean of three independent determinations. For graphical limitations the
SD values (5–10%) were not included in figures. According to general criteria for gene expression amplitude, the degree of the modulation was considered high
(∗∗) for fold values ≥ 2 and medium (∗) for values between 2.0 and 1.5. Protein clusters (A) cytoskeleton and associated proteins, (B) metabolic enzymes, (C)
molecular chaperones/heat shock proteins, (D) membrane-associated and calcium binding proteins, (E) detoxification, degradation and related proteins, and (F)
biosynthesis and proliferation regulators.
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FIG. 5. (Continued).
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38 I. PUCCI-MINAFRA ET AL.
domain-binding glutamic acid-rich-like protein (SH3L1). The
degradation pathway includes the following proteins: protea-
some subunits alpha type 5 and beta type 4 (PSA5, PSB4),
ubiquitin (UBIQ), and the ubiquitin carboxyl-terminal hydrolase
isozyme L1 (UCHL1). Five proteins of the redox pathway,
AK1C3, AK1BA and ALDR, PRDX6, and 1 isoform of THIO,
are drastically reduced in both DEC-C2 and DEC-C3. Other
proteins of both detox and degradation pathways undergo little
changes, while a net increment was observed for the PSA5, 1
isoform of SODM and THIO and for the SH3L1, a putative
modulator of the redox function [34].
Biosynthesis, Cell Growth and Proliferation Regulators
Although proteins belonging to these categories are produced
in rather small amounts, in the present group we detected 10 pro-
teins and 1 protein fragment (Figure 5F): translation initiation
factors IF5A and IF32, the translation elongation factors 1-beta
(EF1B) and EFTU (mitochondrial), the nucleoside diphosphate
kinase A and B (NDKA, NDKB), the ribosomal protein L12
(RM12), the hyaluronan-binding protein 1 (MA32/C1QBP),
the macrophage migration inhibitory factor (MIF), and the
prohibitin (PHB). In particular, 2 of these proteins, MIF, a
pleiotropic factor promoting neoplastic cell proliferation [35],
and the prohibitin, a negatively controller of the cell cycle [36],
showed significant modulations. Interestingly, a net decrease
(∼5-fold) of MIF levels was observed in both DEC-C2 and
DEC-C3 cells versus the parental cells, contrary to the net
increase of PHB.
DISCUSSION
The literature of the past 10 years has produced a great deal
of data concerning the involvement of decorin in cancer. To our
knowledge, the present report is likely the first study focusing
on wide-ranged responses induced by the ectopic expression of
decorin in breast cancer cells. As an in vitro model we utilized
the breast cancer cell line 8701-BC and 2 decorin-transfected
clones: DEC-C2, expressing and producing the full decorin
proteoglycan, and DEC-C3, producing only the protein core.
Introductory results obtained by cell proliferation assays
showed a remarkable antiproliferative effect of decorin, when
either exogenously added or endogenously produced by a
transgene. These results, in agreement with other relevant
studies by other authors, suggest a general mode of action of
decorin, acting from the outside of the cells, either in other breast
cell culture (MCF7) or in cell cultures of various histological
origin [24].
It is known that neoplastic cells are characterized by
abnormal growth, not only because they are more accelerated
than normal counterparts, but also for the anarchical cell-cell
interactions, due to the loss of cell adhesion and the emergence
of spikes, lamellipodia, and other membrane ruffling. All these
perturbations, which are distinctly produced by the parental
breast cancer cells 8701-BC, were definitely restrained in the
decorin-transfected clones.
To investigate wide-ranged effects of transgenic decorin
we performed comparative proteomic analyses on parental
and transfected cells. The obtained data demonstrated that
ectopic decorin, both as proteoglycan and protein core, induces
significant modulation within the protein categories identified
in our experimental system. Within the category of cytoskeleton
and associated proteins, cofilin, profilin, and tropomyosin beta,
were the most responsive to the ectopic decorin in both
clones.
Cofilin and profilin are involved directly in actin polimer-
ization: in both transfected clones we observed a net decrease
of the basic forms of cofilin and profilin and the correspective
increase of the acidic forms. The latter, on the basis of isoelectric
point”estimator”/ calculator (http://www.nihilnovus.com/ Pal-
abra.html), may correspond to the phosphorylated isoforms.
This result is well correlated with the regression of lamellipodia
and other membrane protrusion in the transfected clones versus
the parental 8701-BC cells.
Conversely, tropomyosin (3 isoforms) was more expressed in
both DEC-C2 and DEC-C3 clones, suggesting that the recovery
of more differentiated features of transfected cells also may be
mediated by restored levels of tropomyosin. Other authors have
reported that tropomyosin is downregulated in breast carcinoma
cells [37] that the forced expression of several isoforms of
tropomyosin in cancer cells can suppress their growth or induce
a more differentiated cellular morphology [38, 39]. Related to
cytoskeleton and surface activities are several members of the
annexin family, a class of calcium- and phospholipid-binding
proteins that associate reversibly with membranes, so acting
as scaffolding or bridging proteins [40, for review]. Several
members of this family have been related to cancer progression
[41–43].
Our results show an opposite modulation of ANXA2 (posi-
tive) and ANXA4 (negative) for which we have no explanation
at present, however this is the first report showing a correlation
between decorin actions and annexin expression levels. It is
noteworthy to observe that the other protein category responsive
to the ectopic decorin is that of glycolytic enzymes, which
appeared collectively decreased in both transfected clones, by
an average value of 1.5–2 fold relative intensity.
It is well-known that the tumoral cells have an altered
metabolic pattern. In particular an increment of the anaerobic
metabolism of the glucose has been observed in the presence
of physiological oxygen levels. This phenomenon, known as
Warburg effect, so named after its discovery [44], seems to
be a common phenomenon in the development of the solid
tumors, or in the acquisition of the invasive ability by neoplastic
cells. More recently, magnetic-resonance spectroscopy and
positron-emission tomography studies with 18F-fluoro-deoxy-
glucose have consistently demonstrated that cancer patients
show elevated levels of glucose uptake with respect to normal
subjects [45].
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Current opinion states that these metabolic changes associ-
ated with malignant tumors are not primarily related to cancer
etiology, but they may confer a common advantage on neoplastic
cells in their survival and invasion of surrounding connective
tissues under conditions of low oxygen supply. This suggests
that metabolic alterations in cancer may be due to long-term
gene deregulation associated with some early step of oncogenic
transformation. This hypothesis is further supported by some
preliminary data from our lab indicating a concomitant decorin-
associated mRNA downregulation of two key oncogenes in
breast cancer, c-Myc and c-erbB2 (data not shown). Indeed
both oncogenes are the most commonly amplified oncogenes
in human breast cancer [46, 47] and are involved in the direct
or indirect activation of numerous genes, among which ENOA
and PGK1 [48, 49], as well as MIF andVDAC1 [50], IF5A [51],
HZP27 [49], which we found decreased in both DEC-C2 and
DEC-C3 clones.
Additionally, decorin appears to downregulate the production
of several putative breast cancer biomarkers. Of particular
interest was the observed net decrease of S100A4 in DEC-C2
cells and its absence in DEC-C3. The S100A4 (also referred
to as metastasin, calvasculin, or placental calcium-binding
protein) belongs to the S100-family of proteins and has
been found to stimulate metastatic spread of tumor cells in
association with enhanced expression of the invasivity marker
uPA [52]. Moreover elevated expression of S100A4 is correlated
with poor prognosis in many human cancers [53]. Its net
decrease, or abrogation, following decorin is of primary interest,
given the postulated action of decorin as an antioncogenic
molecule.
The effects of decorin were also associated with opposing
changes in the expression levels of two modulators of cell
cycle: MIF and prohibitin. MIF is a pleiotropic factor and
found frequently overexpressed in primary breast cancers, where
it also has functionally inactivated the p53 tumor suppressor
and inhibited p53-responsive gene expression and apoptosis
[54]. Interestingly, our results show a significant decrease of
MIF levels, both in DEC-C2 and DEC-C3 cells. Conversely,
prohibitin known to be a negative regulator of cell proliferation
and a putative tumor suppressor, shows a significant increase in
decorin-transfected cells.
Concurrently, decorin appears to drastically reduce the
expression levels of several proteins involved in detoxification
pathway, both DEC-C2 and DEC-C3, without extensively
affecting the category of heat shock proteins, which are involved
in many stress responses. Members of the detoxification aldo-
keto reductase family and aldose reductase have been associated
with cancer and are believed to be involved in drug resistance
[55–57]. It is of great interest that the decorin induces a
decrease of these protein expression, concominat with the
increment of the SH3 domain-binding glutamic acid-rich-like
protein (SH3L1) a putative modulator of the redox function
and structurally reconducted to thioredoxin super family
[34].
CONCLUSION
The results of the present study revealed new important
antioncogenic potentialities exerted by decorin, either as a
proteoglycan or as a protein core, through a variety of distinct
biochemical pathways, probably involved in the reversion of
the malignat features of the 8701-BC phenotype toward a more
differentiate state. Major decorin effects include the reduction
of proliferation rate, hyper glycolytic phenotype, exaggerate
membrane ruffling, lamellipodia formation and vesiculation,
and the poor cell-cell adhesiveness. Concurrently, the expression
of ectopic decorin is associated with a net decrease of several
potential breast cancer biomarkers. Moreover, decorin seems to
downregulate the expression of c-Myc and c-erbB2, which in
turn may contribute to the phenotype reprogramming.
Taken together, these results provide new important elements
in support of the potential antioncogenic role exerted by decorin,
disclosing original aspects related to the reversion of malignant
traits of a prototype of breast cancer cells, and raise additional
interest for the postulated clinical application of decorin. At
the same time, the proteomic approach, while disclosing new
putative pathways for the decorin action, presented unexpected
responses concerning a number of proteins, which deserve
future investigations.
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